BioMarin Pharmaceutical(BMRN) - 2025 Q4 - Annual Results

Financial Guidance - BioMarin estimates approximately $3.2 billion in total revenues for the year ended December 31, 2025, including about $920 million from VOXZOGO sales[4] - The company expects an asset write-down related to ROCTAVIAN in Q4 2025 of approximately $230 to $260 million, impacting Non-GAAP EPS by $(0.60) to $(0.64) per share[4] - Excluding the asset write-down, BioMarin's full-year financial guidance for Non-GAAP Diluted EPS remains unchanged from previous estimates[4] Financial Reporting - The results presented are preliminary and unaudited, subject to normal accounting procedures, with final results expected in February 2026[5] - BioMarin's financial updates were made available through a webcast and accompanying slides on their website[5] Non-GAAP Measures - BioMarin emphasizes the importance of both GAAP and Non-GAAP metrics for assessing financial performance and making business decisions[12] - Non-GAAP Income excludes amortization of intangible assets and stock-based compensation, providing a clearer view of operational performance[11] - The company plans to continue using Non-GAAP measures to enhance comparability of results over time[12] - Investors are advised to consider Non-GAAP measures in conjunction with GAAP information for a comprehensive understanding of financial performance[13] Forward-Looking Statements - The company is under no obligation to update forward-looking statements, which may be subject to risks and uncertainties[10]